ArticleFrontiers in cellular and infection microbiology2026
Multi-omics integration of gut-skin axis in probiotic-treated dermatological conditions.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The gut-skin axis is an integrated biological communication network linking gut microbial metabolites, immune regulation, oxidative stress responses and skin barrier function. Dysregulation of inflammatory and metabolic pathways has been associated with dermatological disorders including psoriasis, eczema and atopic dermatitis. Postbiotic metabolites derived from probiotics are increasingly recognized for their anti-inflammatory, antioxidant and immunomodulatory activities that may contribute to skin homeostasis. Here, we aimed to investigate the multi-omics effects of probiotic metabolite extracts (PMEs) in an Methods: HaCaT keratinocytes and Human Dermal Fibroblast (HDF) cells were employed as complementary Results: After PME treatment, keratinocyte viability was significantly higher (95.4%) compared with the inflammatory control group (62.4%). Pro-inflammatory cytokine levels were significantly decreased (TNF-α: 86.7 to 28.9 pg/mL; IL-6: 79.5 to 25.7 pg/mL), intracellular ROS decreased from 248 RFU to 116 RFU, and antioxidant enzyme activities were restored. Metabolomic profiling showed increased levels of short-chain fatty acids (SCFAs) such as butyrate (1.24 to 3.02 µmol/g), which are beneficial to the skin. Transcriptomic and qRT-PCR analyses showed upregulation of genes associated with the skin barrier, such as FLG (1.28-fold), LOR (1.31-fold) and IVL (1.29-fold). Discussion: Integrated multi-omics analysis suggested that PMEs may modulate inflammatory signaling and enhance epidermal barrier-related gene expression through coordinated metabolic and transcriptional regulation, which may validate the therapeutic potential of probiotic-derived metabolites as candidate adjunctive strategies for inflammatory skin disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.